CHRISTOPHER Y. THOMAS IV, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: The recent article by Dr. Wu (Ann Intern Med 88:7-11, 1978) adds valuable data to the study of platelet disorders in patients with myeloproliferative diseases. I have, however, several reservations about the implications of this study.
Dr. Wu successfully treated six patients suffering thrombotic symptoms with the antiplatelet drugs aspirin and dipyrimadole. There are potential problems with this approach. Many authors have described patients with manifestations of both thrombosis and hemorrhage (1, 2). Adams, Schutz, and Goldberg (3) have shown an exaggerated response of the bleeding time in several patients with myeloproliferative disorders given aspirin. We recently
THOMAS CY. Platelets in Thrombocythemia. Ann Intern Med. ;88:845–846. doi: 10.7326/0003-4819-88-6-845_1
Download citation file:
Published: Ann Intern Med. 1978;88(6):845-846.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use